Why Tubulis gives Gilead more than just another antibody-drug conjugate asset
Gilead is acquiring Tubulis to expand its antibody-drug conjugate pipeline. Read what the deal changes for oncology strategy and ADC competition.
Can Synthekine’s STK-012 overcome immunotherapy resistance in first-line NSCLC patients?
Can STK-012 overcome immunotherapy resistance in lung cancer? Explore AACR 2026 data and what it means for IL-2 precision therapies.
Why the TACTI-004 Phase III outcome challenges assumptions about LAG-3 immune activation
Immutep Limited halts its TACTI-004 lung cancer trial after a futility analysis. Discover what the setback means for eftilagimod alfa and LAG-3 immunotherapy.
Junshi Biosciences pushes subcutaneous PD-1 therapy as China’s oncology system strains
NMPA reviews subcutaneous toripalimab across 12 cancers. Discover how the delivery shift could reshape China’s immunotherapy infrastructure.
Partner Therapeutics’ zenocutuzumab data adds nuance to progression-driven treatment decisions in NRG1-positive lung cancer
Find out how zenocutuzumab treatment beyond progression could change care for NRG1 fusion-positive lung cancer and what clinicians should watch next.
Why Lilly’s LIBRETTO-432 results matter beyond selpercatinib’s event-free survival win
Eli Lilly and Company (Lilly) announced that its selective RET inhibitor selpercatinib, marketed as Retevmo, achieved a highly statistically significant improvement in investigator-assessed event-free survival when used as adjuvant therapy in patients with stage II–IIIA RET fusion-positive non-small cell lung cancer, based on topline results from the Phase 3 LIBRETTO-432 trial. The study compared selpercatinib […]
MAIA Biotechnology advances ateganosine cancer program with Phase 3 THIO-104 trial and 2026 catalyst timeline
Find out how MAIA Biotechnology is advancing ateganosine into Phase 3 and why its 2026 clinical milestones could reshape treatment options in lung cancer.
What D3 Bio’s dual KRAS IND clearances reveal about the next wave of targeted oncology
D3 Bio secures U.S. FDA IND clearances for two KRAS programs, advancing G12D monotherapy and G12C resistance combo trials. See what this means for oncology.
Janux Therapeutics advances masked EGFR T cell engager JANX008 into Phase 1 expansion
Janux Therapeutics pushes JANX008 into Phase 1 expansion across EGFR+ cancers. Discover how masking technology may shift the immunotherapy safety paradigm.
Why Verastem Oncology’s KRAS G12C trial exit reveals a calculated pivot to next-generation lung cancer targets
Verastem exits its G12C lung cancer trial to prioritize VS-7375, a next-gen G12D inhibitor showing promise. Find out how this pivot could change KRAS therapy.